

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., ACTAVIS
LABORATORIES FL, INC., AMNEAL PHARMACEUTICALS LLC,
AMNEAL PHARMACEUTICALS OF NEW YORK, LLC, DR. REDDY'S
LABORATORIES, INC., DR. REDDY'S LABORATORIES, LTD.,
SUN PHARMACEUTICALS INDUSTRIES, LTD.,
SUN PHARMACEUTICALS INDUSTRIES, INC.,
TEVA PHARMACEUTICALS USA, INC., WEST-WARD
PHARMACEUTICAL CORP., and HIKMA PHARMACEUTICALS, LLC,
Petitioner

v.

JANSSEN ONCOLOGY, INC.,

Patent Owner

Case IPR2016-01332¹
Patent 8,822,438 B2

**REPLY DECLARATION OF JOHN BANTLE, M.D.
IN SUPPORT OF PETITION FOR *INTER PARTES* REVIEW OF U.S.
PATENT NO. 8,822,438**

¹ Case IPR2017-00853 has been joined with this proceeding.

TABLE OF CONTENTS

	Page
I. Qualifications and Background.....	4
A. Education and Experience.....	4
B. Bases for Opinions.....	5
C. Retention and Compensation	6
II. Summary of Opinions	6
III. Legal Standards	8
IV. Person of Ordinary Skill in the Art	9
V. Background	10
A. The Three Major Steroid Pathways: Androgen, Glucocorticoid, and Mineralocorticoid	10
B. Adrenal Steroid Synthesis Inhibitors	12
C. Adrenal Insufficiency and Mineralocorticoid Excess	18
VI. Opinions.....	25
A. A POSA Would Have Been Motivated to Administer Prednisone With AA With A Reasonable Expectation of Success	25
1. A POSA would have been motivated to administer prednisone with abiraterone acetate because ketoconazole, another CYP17 inhibitor, was known to cause adrenal insufficiency and was therefore administered with a glucocorticoid.....	25
2. O'Donnell would have motivated a POSA to administer prednisone with abiraterone acetate to protect against adrenal insufficiency or compromised adrenal reserve	29
3. A POSA would have been motivated to administer prednisone with abiraterone acetate to prevent mineralocorticoid excess.....	33
4. For all three conditions (adrenal insufficiency, low adrenal reserve, and mineralocorticoid excess), a POSA would have reasonably expected administration of prednisone to resolve patient symptoms	38

TABLE OF CONTENTS
(continued)

	Page
B. Dr. Auchus’s Criticisms of O’Donnell Do Not Refute Motivation	39
1. The other information reported in O’Donnell would not have diminished the Synacthen results.	40
2. Dr. Auchus’s criticisms fail to undermine O’Donnell’s Synacthen test results	44
3. O’Donnell’s contemporaneous conclusions contradict Dr. Auchus’ opinions	50
C. Dr. Auchus’s Criticisms of the ’213 Patent Do Not Refute Motivation	51
D. Dr. Auchus’s Analogies to Genetic CYP17 Deficiencies Do Not Teach Away From Co-Administration of Abiraterone Acetate With Prednisone	53
E. A POSA in 2006 Would Have Administered Glucocorticoid Replacement Therapy Over Other Options	57

I. Qualifications and Background

1. My name is John Bantle, M.D. I have been retained by Petitioner in the matter of the *Inter Partes* Review (IPR) of U.S. Patent No. 8,822,438 (the “438 Patent”), as set forth in the above caption.

A. Education and Experience

2. I am a medical endocrinologist and Professor Emeritus of Medicine in the Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, at the University of Minnesota. I have substantial experience in clinical research, treatment of patients, and academic publication in the field of endocrinology.

3. I received a Bachelor of Science degree in 1970 from the University of Minnesota and a Doctor of Medicine degree in 1972 from the University of Minnesota Medical School. I completed an internship at Cleveland Metropolitan General Hospital in 1973; residencies in internal medicine at the Mayo Clinic in Minnesota and Dunedin Public Hospital in Dunedin, New Zealand in 1975 and 1976, respectively; and a fellowship in endocrinology and metabolism at the University of Minnesota in 1978.

4. In addition to my teaching positions, I have held multiple clinical research positions throughout my career. I was the Associate Director of the General Clinical Research Center at the University of Minnesota Medical School from 1983–2009, the Medical Staff Clinical Service Chief for Internal Medicine at

Fairview-University Medical Center from 2001–2007, and the Clinical Research Implementation Services Leader of the Clinical and Translational Science Institute at the University of Minnesota from 2011–2013. In addition, I have participated in numerous clinical trials, both as principal investigator and co-investigator. I have authored approximately 150 publications, book chapters, and presentations on the topics of endocrinology and metabolism.

5. I have received numerous honors and awards for teaching, clinical excellence, and treatment of patients. For example, I was named by the Best Doctors Organization as one of the Best Doctors in America for twenty consecutive years from 1996–2015; I was named a Top Doctor by Minneapolis/St. Paul Magazine in 1992, 1994, 1996, 1999–2002, 2004, and 2006–2017; and I received the University of Minnesota Department of Medicine Clinical Excellence Award in 2002, 2004, and 2011.

6. My *curriculum vitae* is attached as Exhibit A to this declaration.

7. Based upon my education, training and experience, as summarized above, I believe I am qualified to provide opinion testimony as an expert in endocrinology.

B. Bases for Opinions

8. The opinions to which I testify are based on the education, experience, training and skill that I have accumulated in the course of my career as a practicing

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.